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1. Introduction 
The nervous system is commonly involved by SLE. Its involvement classified as primary 
when it is related to the disease process and secondary when it is related to other factors like 
medication side effect or infection. The nervous system involvement by lupus was described 
by Hebra and Kaposi in 1875 who described a patient with lupus and coma (Appenzeller et 
al.,2006). Shortly after Bowen report case of psychosis and mood disturbance (Appenzeller 
et al., 2006).  
The nervous system involvement rang from overt presentation to more subtle finding. In 
spite the advances in SLE diagnosis and managements, the neuropsychiatric syndromes 
remain one of the major causes of morbidity and mortality in SLE patients. Still they remain 
poorly understood and under recognised. The aim of this chapter is provide an overview of 
neurological presentation in SLE patients. 
2. Definition 
As there is wide Varity of different neurological and psychiatric presentations among SLE 
patient, the American college of Rheumatology (ACR) established in 1999 19 different 
neuropsychiatric SLE (NPSLE) syndromes (table-1). Either central or peripheral nervous 
system can be affected by the disease process. Their involvement can be generalized e.g 
headache, cognitive dysfunction or focal e.g. cerebrovascular disease and demyelinating 
syndromes. 
Before attributing any of the neuropsychiatric (NP) manifestation to SLE secondary causes 
should be ruled out. As most of SLE patient are immunocompromised either by the disease 
process or secondary to immunocompressive therapy infection is a common problem in this 
patients. Other secondary causes can be metabolic impairments or complication from 
hypertension e.g posterior reversible leukoencephalopathy. 
3. Epidemiology 
The reported prevalence of NPSLE is varied from 37- 95 %(Muscal & Brey,2010) depending 
on the case definition used and the inclusion criteria. Most of NPSLE affect central nervous 
system(91.6%) and out of those 79% are diffuse in nature and 21% focal(Hanly et 
al.,2008).The peripheral nervous system involvement is much less than CNS involvement.  
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NPSLE Associated with Central Nervous 
System 
NPSL Associated with Peripheral Nervous 
System  
 
‐ Aseptic Meningitis 
‐ Cerebrovascular disease 
‐ Demyelinating syndromes 
‐ Headaches 
‐ Movement Disorders ( Chorea) 
‐ Myelopathy  
‐ Seizure Disorders 
‐ Acute Confusional State 
‐ Anxiety Disorders 
‐ Cognitive Dysfunction 
‐ Mood Disorders 
‐ Psychosis 
 
 
 
‐ Acute Inflammatory 
Demyelinating Syndromes ( 
Gulliain –Barre Syndrome) 
‐ Autonomic Neuropathy 
‐ Mononeuropathy, single or 
multiplex 
‐ Myasthenia Gravis 
‐ Cranial Neuropathy 
‐ Plexopathy 
‐ Polyneuropathy  
 
Table 1. Neuropsychiatric Syndromes Associated with SLE 
The most frequently reported PNS involvement is peripheral neuropathy between 2.4to 7% 
(Hanly et al.,2010)(Ainiala et al.,2001). Recently Hanly and his colleague conducted a large 
cohort of SLE patients. They reported around 40.3% of SLE patient had at least one NP event 
and 17.4% had recurrent events (Hanly et al.,2010). The most frequent NP was headache 
47.1% followed by mood disorders in 16.5%, Seizure in this cohort reported in 7.5% and 
cognitive dysfunction in 5.1%.  
In other studies when a mild cognitive impairment and mild mood disorders were included 
higher prevalence of NPSLE is 80-91% (Ainiala et al.,2001)( Brey et al.,2002). When formal 
neuropsychiatric evaluation is used cognitive dysfunction is reported in 80% of the patient 
(Ainiala et al.,2001)( Brey et al.,2002). In 70% of those are classified as mild cognitive 
impairment with impairment of one or two cognitive domains (Ainiala et al.,2001). 
The reported prevalence of cerebrovascular accident range between 4.7 to 15% (Hanly et al., 
2010) (Ainiala et al.,2001). 
The prevalence of other NPSLE syndromes is much less with reported prevalence of 
demyelinating syndrome and movement disorder of 1%. 
CNS manifestations present as an initial feature of SLE in 24% of cases (Joseph et al.,2007). In 
general around 50-60% of NPSLE occurred at disease onset or within the first year after SLE 
onset. 
3.1 Risk factors 
Risk factors associated with CNS involvements are:- 
1. Generalized disease activity. 
2. Prior history or concurrent NPSLE. 
3. Presence of antiphospholipid  antibodies especially for focal CNS lesions and seizure 
(The European League Aganist Rheumatism EULAR, 2010).It was also noted that 
patients with APS who had a history of two or more abortion are six times more likely 
to have CNS events(Karassa et al.,2000). 
In term of SLE disease activity two studies have shown that skin lesions are the most 
frequent lesions associated with CNS disease (EULAR, 2010)( Karassa et al.,2000). Two 
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studies have shown a protective effect of arthritis to CNS disease ((EULAR, 2010). This was 
not consistent in other study were arthritis was a second common manifestation after skin 
disease (Joseph et al.,2007). 
4. Pathogenesis 
The neuropsychatric lupus has different manifestations. As the manifestations can be 
generalized or focal no single pathophysilogical mechanism has been implicated in its 
pathogenesis.   Different mechanisms are thought to affect the nervous system and caused 
the development of NPSLE.  Those different mechanisms include vasculopathy, 
autoantibodie and cytokines. 
4.1 Vasculopathy 
Vascular occlusion is universally reported in autopsy cases in patient with lupus. Although 
vasculitis is thought to be the cause of small vessels disease in lupus patient, its occurrence 
is rare. The most frequent cause is found to be a non inflammatory vasculopathy.  
On pathology multiple microinfracts, cortical atrophy, gross infracts were seen on the brain. 
Microhemorrhages are common in NPSLE . Larger haemorrhages like intracerebral are rare. 
The most common vascular pathology is noninflammatory lesions characterized by 
endothelial proliferation, intimal fibrosis and lymphocytic infiltration. It may associated by 
thrombosis (Ellison et al.,1993). 
The pathogenesis of the vascular injury initially thought to be secondary to immune 
complex deposition but now it thought to be secondary to complement activation (Muscal & 
Brey, 2010). 
4.2 Autoantibodies 
Autoantibodies play a major role for the development of different manifestations of SLE. 
Different antibodies have been reported in association with NPSLE. Among those the most 
frequent antibodies are antiphospholipid (APl) and antiribosomal abs. 
Antiphospholipid antibodies that includes lupus anticoagulant, anti cardiolipin and anti-
beta2 glycoprotein I antibodies are groups of antibodies which target the phospholipid 
binding plasma proteins such as beta 2 glycoprotein I and prothrombin. As they alter the 
expression and secretion of procoagulant on the cell surface they subsequently prompt 
thrombosis.  
Their presences were associated with recurrent thrombosis and fatal losses. Multiple 
neurological presentations are linked to their presence in patient with and without SLE. It 
associated in particular with focal neurological events like stroke. They also have linked to 
seizure, movement disorders, cognitive impairment and myelitis. 
A subset of anti- DNA antibodies were found to react with NR2 glutamate 
receptors.Glutamate is an exiatatory neurotransmitter in the brain. It react with NMDA( N- 
methyl-D-aspartate) receptors which is present throughout the brain tissue. NMDARS that 
containing NR2A andNR2B are more expressed in CA1 region of the hippocampus and the 
amygdale. Excessive stimulation of NMDARS results into excessive influx of calcium into 
the neuronal tissue causing mitochondrial stress and subsequent neuronal death (Aranow et 
al, 2010). 
In animal models anti NR2 receptors antibodies did not cause brain damage in the 
presence of intact blood brain barrier (BBB). When BBB compromised using bacterial 
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lipolysaccharide (LPS) damage to hippocampal neurons took place with no evidence of 
inflammation. Those mice performed badly on memory function (Kowal et al,2004). When 
epinephrine is used to compromise the BBB the hippocampus of those mice was normal 
but the antibodies react with neurons of the amygdale. Those mice had impaired fear 
response (Huerta et al.,2006). 
Studies have shown a correlation between the CSF anti- NR2 level with diffuse NPSLE not 
with focal NPSLE (Arinuma et al, 2008) and no relation to serum anti-NR2 level. This may 
implicate intrathecal production of anti-NR2 antibodies or migration of antibodies through 
compromised BBB. 
Anti- ribosomal P antibodies was reported in association with SLE. Their presence was 
linked to lupus related Psychosis and depression. 
4.3 Cytokine effects 
Elevated level of interleukin (IL-1),IL2,  IL-6, IL-8, and interferon gamma (IFNϒ) were found 
in the  CSF of patient with NPSLE (Rhiannon, 2007)(Chandy et al.,2008).  Also elevated level 
of tumour necrosis factor ( TNF) family ligands BAFF (B- cell activating factor of TNF 
family) and APRIL ( a proliferation- inducing ligand) were seen in CSF of SLE patients. 
However the level of APRIL was higher in NPSLE patients when compared to SLE patient 
without NP (Chandy et al,2008). 
The cytokines are thought to be produced locally by the infiltrating immune cells or by the 
glial cells or the neurons. Different cytokines had different effects. Their role in the 
pathogenesis of NPSLE is related to stimulating antibodies productions, effecting 
neurotransmitter release and the release of corticotrophin releasing hormone (CRH). The 
stimulation of glucocorticoid production results in persistent elevation of glucocorticoid that 
plays a role in hippocampal atrophy. 
5. Approach 
A careful evaluation of SLE patients presenting with new neurological symptoms and signs 
is needed to rule out secondary causes before attributing it to SLE. Different secondary 
causes can be a cause for neurological symptoms in SLE patients. The management will be 
different if the presentation related to lupus or to other causes.  
The evaluation of SLE patients presenting with neurological symptoms and signs will be the 
same as non SLE patients. This includes careful clinical, laboratory and imaging studies. The 
diagnosis of NPSLE is a diagnosis by exclusion. No single laboratory or imaging study will 
confirm that the neurological presentation is caused by SLE itself. The presence of other 
lupus related activity could support the diagnosis of NPSLE. 
5.1 History 
Detailed history is mandatory when evaluating lupus patient presenting with new 
neurological presentation. Detailed description of the neurological symptoms is necessary to 
assist for localization and identifying a potential cause for the problem. The onset of the 
symptoms will help identifying problems with acute versus more chronic disorder. The 
severity of the presentation and associated other neurological symptoms will help in 
determine the nature and will assist further regarding the management plan.  The presence 
of fever may suggest the presence of infection. 
www.intechopen.com
 
Approach to Patients with SLE Presenting with Neurological Findings 
 
341 
Detailed SLE history regarding time of diagnosis, disease course, previous neurological 
presentation and complications related to disease are particular important. Most of NPSLE 
present at time of generalized disease activity. Patients with prior neurological involvement 
are also at higher risk to have recurrence or development of other neurological disorders. 
Neurological complications can be also developed secondary to other organ involvement by 
lupus for example acute stroke can be a presentation of libman Sacks endocarditis , or in 
other example patient may develop posterior reversible leukoencephalopathy (PRES) 
secondary to hypertension which can be secondary to renal disease in lupus patient. 
Detailed drug history is important as patient may develop complication related to therapy 
like psychosis from steroid therapy. Patient on immunosuppressive treatment are 
immunocompromised so they are at high risk of development of bacterial, viral and fungal 
infections. Subacute neurological symptom in SLE patient may represent JC virus infection 
that causes progressive multifocal leukoencephalopathy (PML). PML is a demylinating 
disease that mainly reported with HIV patients.  Multiple cases of PML also reported in SLE 
patient either on or not on immunosuppressive therapy (Molloy &Calbrese, 2009).The 
possibility of infection should be ruled out before attributing a neurological presentation to 
SLE and starting aggressive immunosuppressive therapy. 
Other medication history might be the cause for the neurological presentation. In particular 
antipsychotic therapy as they can induce movement disorders. The management in that 
instance will necessitate medication changes rather than immunosuppression. 
Detailed family history of same problem or other neurological disorders may point to 
genetically related neurological diagnosis not necessary attributing it to SLE. 
When patient present acutely with symptoms and signs suggestive of acute stroke a quick 
assessment is necessary not to delay thrombolytic therapy if indicated (further discussion 
regarding cerbrovascular disease is discussed below). 
In patient presenting with seizure careful history to characterize the seizure whether it is 
generalized or focal. The presence of focal seizure could represent structural lesion as a 
cause of the seizure. Careful medication and systemic review is mandatory as the seizure 
can be secondary to metabolic abnormalities e.g. uremia or medication induced seizure. The 
presence of other associated neurological symptoms could point to other possible causes of 
seizure. In particular the presence of headache, disturb conscious level could be related to 
posterior reversible leukoencephalopathy, limbic encephalitis or viral encephalitis. The 
presence of other focal neurological deficit can point to structural lesions such as stroke. One 
should exclude other non lupus related causes of seizure such as head trauma or genetically 
determent epilepsy. 
5.2 Examination 
The aim of the examination is to localize the neurological presentation and reach a possible 
diagnosis which will be supported by the laboratory investigations. 
Careful systemic as well neurological examinations are required when dealing with SLE 
patients with neurological presentation. In particularly patient need to checked for fever, 
and had blood pressure measurements. The presence of other area of vascular occlusion 
could point to vascular cause of the neurological events. 
In patient presenting with cognitive problem full neuropsychological assessment should be 
carried out. That will include assessing simple attention, complex attention, memory, 
visuospatial processing, language, reasoning/problem solving, psychomotor speed and 
executive functions. 
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5.3 Laboratory examination 
Full laboratory assessment to rule out infection and metabolic abnormality that could be the 
cause for the neurological events. That will include complete blood count, electrolytes, 
kidney and liver function test.   
Cerebrospinal fluid assessment is necessary in certain cases to rule out infection or other 
unrelated condition. In patient with subacute presentation and demylination on imaging the 
CSF should be sent for JC virus PCR. The CSF level of autoantibodies and inflammatory 
mediators are not recommended now as it still a research interest. 
5.4 Supplementary tests 
EEG is indicated in patient presenting with seizure or in patient with acute confusional 
state. For patient with seizure the EEG will help in determine the subset of patients who are 
at high risk of seizure recurrence. The most frequent EEG abnormalities reported in SLE 
patient is bitemporal slowing in 65% of patients ( Lampropoulos et al., 2005). 
Nerve conduction study and electromyography is indicated in patient presenting with 
peripheral nervous system related complaints.  
5.5 Imaging 
In acute setting in patient presenting with acute onset neurological events computerized 
tomography  (CT) brain is the imaging modality of choice to rule out haemorrhage. It is also 
an easily accessible and widely available. The use of CT brain initially will be important to 
identify a subset of patients who may need thrombolytic therapy.  
MRI (magnetic resonance imaging)is a preferred imaging modality to evaluate lupus 
patients with neurological symptoms. It is more sensitive than CT in detecting anatomical 
abnormalities and determines the extent of disease process. The most frequent abnormalities 
in MRI is hyperintense white matter lesions which is seen in 70% of patients (Appenzeller et 
al.,2007).Their presence have been linked to the presence of Apl . Cerebral atrophy is seen in 
6-12% in SLE patients (Huizinga et al.,2001)(Appenzeller et al.,2005-2007). 
Other advanced imaging technique may be of value in assessing patients with NPSLE 
although there clinical uses are not widely available. Those includes MTR ( magnetization 
transfer ratio), diffusion weighted images, MRS (magnetic resonance spectroscopy), 
functional MRI and single photon emission computed tomography.  
 
Investigation  
Laboratory                                   CBC, Electrolytes, Kidney and liver function 
CSF                                                WBC, Glucose, protein,  
                                                       Gram stain and culture 
                                                       Viral PCR 
Imaging                                        CT brain 
                                                       MRI brain and spinal cord 
Electrophysiology                       EEG 
                                                       EMG 
CBC, complete blood count; WBC, white blood cell; CT computerized tomography; MRI , magnetic 
resonance imaging; EEG, electroencephalogram 
Table 2. Recommended investigation in SLE patient with neurological presentation 
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6. Management 
Once the diagnosis of NPSLE is confirmed the treatment will include treatment of potential 
aggravating factors, symptomatic treatment for the events and more specific treatment 
related to SLE itself. 
In some condition symptomatic treatment will be required first before specific therapy is 
indicated. For example in patient presenting with seizure after excluding secondary causes 
starting antiepileptic is required before the decision on specific treatment is made(Hanly & 
Harrison, 2005). 
The severity and the nature of neurological events will also play a role in the decision on 
treatment. For example patient with non serious headache will require only symptomatic 
treatment. 
In the presence of severe neurological disease the Europan League Aganist Rheumatism ( 
EULAR, 2010) recommends the use corticosteroid alone or with cyclophosphamide.  A 
Cochrane review of cyclophosphamid versus methylprednisolone in treatment of NPSLE 
did not find a randomised clinical trial comparing the two.  
When patient failed to respond to conventional treatment or in the presence of severe 
disease multiple reports suggested the addition of other treatment modalities can be 
effective. Those include plasma exchange, rituximab or intravenous immunoglobulin. 
The combination of the treatment modalities ( cyclophosmaide/corticosteroid/ plasma 
exchange(Bartolucci et al.,2007) or plasmapheresis alone or with cyclophosphamide 
(Neuwelt,2003)) was evaluated in small series of refractory disease. Results from those 
showed favourable outcome with combination modalities. 
Rituximab is an anti-CD20 antibody that directly target B cells. Rituximab was studied in 
refractory cases of NPSLE and showed a rapid improvement of clinical as well radiological 
finding in those patients (Takunaga et al.,2006). 
In the presence of thrombotic disease the management will depend whether patient had 
arterial versus venous thrombosis and the presence of antiphospholipid.  Anticoagulation is 
recommended for venous thrombosis as well in the presence of arterial thrombosis with 
antiphospholipid antibodies.  In absence of antiphospholipid antibodies and the presence of 
arterial thrombosis careful evaluation and management for secondary risk factors with the 
use of antiplatelets are indicated. 
7. Common neurological disorders associated with SLE 
7.1 Headache 
Headache is one of the most commonly reported neurological symptoms associated with 
SLE. There is no specific type of headache found to have increase prevalence in patient with 
SLE (Mitsikostas,2004). 
When patient with SLE patient present with acute headache, special attention is 
warranted to rule out infection, aseptic meningitis and venous sinus thrombosis. On 
examination special attention is required looking for fever, meningeal signs and 
examination for the fundi to rule papilledema. In the presence for focal finding, 
papilldema or altered mental status brain imaging is required. Brain MRI with venogram 
is preferred to rule out venous sinus thrombosis. In presence of fever or signs of infection 
CSF examination is mandatory. 
No specific treatment is required for nonspecific headache. 
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7.2 Cognitive dysfunction 
It is one of the most commonly reported NPSLE syndromes. Most of the patient had mild to 
moderate impairment, only around 3-5% had severe impairment ( EULAR, 2010).  The most 
commonly reported abnormality is overall slowing, decrease memory, impaired working 
memory and executive dysfunction (Hanly,2005). 
Different report linked cognitive impairment to the presence of Apl (McLurin et al.,2005)( 
Denburg et al, 1997).  It is also reported in patient who suffered from stroke and with Apl 
microinfracts although the pattern is different between the two. Cognitive dysfunction 
from stroke develops acutely and remains the same in contrast to those with microinfract 
as it shows stepwise deterioration. Different studies have showed a contradicting results 
regarding the association between global disease activity and the presence of cognitive 
impairment (Kozora et al.,1996)(Hay et al.,1992)(Carbotte etal.,1995). Some of the studies 
found an association and other did not found any association.  The use of glucocorticoid 
associated with cognitive impairment in middle age patients irrespective of disease 
activity (McLurin et al.,2005). The effect of prednisone use was not significant for young 
and old patients. 
Other causes can alter the cognitive function. Of those the development of mood disorders 
are particularly important. It is very well known that depression worsen cognitive function 
and even cause a pseudodementia. Patients with SLE also under psychological stress from 
the disease itself or from medications and that also can alter cognitive function even in 
absence of psychiatric disease (Hanly,2005). 
Formal neuropsychological testing is required to diagnose cognitive dysfunction. The main 
limitation of formal neuropsychological testing is time consuming and it need to be 
administered by an expert.  The minimental test is not a good tool for screening for cognitive 
impairment. 
MRI is indicated if the patient is less than 60 years, rapid and unexplained moderate to 
severe impairment, recent and significant head trauma, presence of other neurological 
symptoms or signs and the development of it in the setting of immunosuppressive therapy 
or antiplatelets (EULAR, 2010). 
Patient should be screened and treated for potential precipitating factors such as metabolic 
and endocrine abnormalities. Associated psychiatric disorders should be treated. Control of 
cardiovascular risk factors also is recommended. Mclaurine in 2005 reported a beneficial 
effect of regular aspirin use on cognitive function in elderly patient with other vascular risk 
factors particularly in diabetics (McLurin et al.,2005). 
The use of glucocorticoid with or without immunosuppressive will be considered in the 
presence of SLE disease activity or other NPSLE events. 
Memantine is a drug used to treat dementia.  One randomized clinical trial looked at the use 
of memantine to treat patient with SLE and cognitive impairment. No significant 
improvement in cognitive function in the treated group. At current the use of memantine for 
SLE patient with cognitive impairment is not recommended. Further clinical trial is needed 
(Petri et al.,2011). 
7.3 Cerbrovascular disease 
SLE patients are at high risk of developing vascular complications. Among those are stroke 
and transit ischemic attacks.  Multiple causes can lead to strokes in SLE patients.  The most 
frequent cause is atherosclerotic diseases. Other rare causes include embolic strokes from 
libman Sacks endocarditis and cerebral vasculitis. 
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In study of carotid ultrasound in asymptomatic SLE patients carotid plaques were seen in 
25-40% of patients. Different risk factors were associated with the development of strokes in 
SLE patients. Those includes high disease activity, moderate to high titres of 
antiphospholipid antibodies, heart valve disease, hypertension, age and smoking (EULAR, 
2010) (Toloza et al,2004)(Bessantbet al.,2004)(Futrell & Millikan,1988). 
Evaluation of stroke/TIA patient will be the same as non SLE patient. Thrombolytic therapy 
can be given unless there are contraindications. Patient should be screened for 
cardiovascular risk factors and have aggressive measures to control them.  Further 
managements will include the use of antiplatelet and carotid endartectomy if indicated. 
Patients who fill full the criteria of antiphospholipid syndromes chronic anticoagulant 
therapy is indicated with a target INR of 2-3 (EULAR,2010)(Crowther et al,2003)(Finazzi et 
al.,2005). 
7.4 Seizure 
Seizure in SLE patient can be attributed to the disease activity or it could be related to 
secondary causes. The secondary causes of seizure in SLE patients are:- infection, 
electrolytes abnormalities, uremia, hypertension, medication side effect or hypoxia. It also 
can be a presentation of unrelated condition such as brain tumours. 
The reported prevalence of seizure is between 7.5% to 14% ( Hanly et al.,2010)(Mikdashi et 
al.,2005)(Appenzeller et al.,2004). Seizure present at disease onset in 31.7% of patients 
(Mucal & Brey,2010), and most frequently occurred within 5 years from diagnosis. Most of 
the patient 88.3% had single events and around 11.7% had epilepsy.  The most frequently 
reported seizure type is generalized tonic clonic seizure followed by complex partial seizure. 
Seizure can present as the only NP syndrome or accompany other neurological events 
mainly ischemic or hemorrhagic strokes and psychosis. 
Multiple studies confirmed the relation between seizure and the presence of Apl(Mikdashi 
et al.,2005)( Appenzeller et al.,2004 )(Gibbs & Husain,2002)(Herranza et al.,1994)(Liou et 
al.,1996). Also the presence of Apl were associated with shorter time to seizure occurrence 
(Andrade et al.,2008). Seizure occurrence is related to high diasese activity, severe organ 
damage in particular nephritis and the presence of Apl. Factors associated with epilepsy are 
the same as those associated with seizure. Patients who had epilepsy are more likely to be 
men (Mikdashi et al.,2005) and more likely to have abnormal MRI and EEG. 
The most frequent abnormality reported in brain MRI in patient with seizure is global 
atrophy and the presence of multiple subcortical hyperintense lesions.  The most frequent 
EEG finding is diffuse slowing. The presence of interictal epileptic activity is associated with 
high recurrence rate of epileptic seizure. 
As most of the patients will have only one seizure, treatment with antiepileptic is not 
recommended. The patient should be investigated with EEG, brain MRI and have Apl 
antibody screening. Patient who had positive test for Apl should be monitored carefully as 
they have high recurrence rate. In the presence of other SLE activity or flare treatment with 
glucocorticoid with or without immunosuppressive is recommended (EULAR, 2010). 
7.5 Acute confusional state 
It is a condition characterized by acute onset of altered mental state with decrease attention. 
A carful exclusion of secondary causes such as metabolic, infection and side effect of 
medications is mandatory. CSF examination is required to exclude infection. Brain imaging 
is indicated to rule out structural lesions. EEG is also indicated to rule out seizure disorders. 
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Treatment includes symptomatic treatment with antipsychotics to control agitation, 
glucocorticoid and immunosuppressive agents. 
7.6 Myelopathy 
Patient with SLE may present with symptoms and signs of spinal cord dysfunction which 
may indicate the presence of myelitis.  Myelitis is less commonly reported than other 
NPSLE syndromes ( 1-3% of patient) (Lukjanowicz & Brzosko,2009). Most commonly 
patient will present with acute transverse myelitis and less commonly will have 
longitudinal myelitis. 
Acute transverse myelitis involves less than 4 segments of the spinal cord in contrast to 
longitudinal myelitis which involve more than 4 segments of the cord. The thoracic cord is 
the most commonly affected followed by the cervical cord (D’Cruz et al.,2004). 
Around 73% of SLE patient presenting with myelitis were positive for apl (D’Cruz et 
al.,2004). 
Patient with myeliitis present acutely with motor weakness and sensory symptoms. The 
extent of the symptoms depends on the level of the lesion and the extent of the 
inflammatory changes. Bladder and bowel dysfunction is seen in all patients with myelitis.  
Lupus myelitis is usually developed in the first 5 years after disease onset (Kovacs et 
al.,2000)(Chan & Boey, 1996). One third of the cases have another major NPSLE 
(EULAR,2010). In 21-48% of patients will have associated optic neuritis (Kovacs et al.,2000) 
(Chan & Boey, 1996) . The recurrence rate for myelitis is seen in 21-55% of patients (Kovacs 
et al.,2000)( Chan & Boey, 1996)(Lehnhardt et al.,2006). 
When patient with SLE present with feature of myleopathy a careful exclusion of other 
causes of myeolpathy is necessary before attributing the presentation to SLE. A contrast 
enhanced MRI of spinal cord is mandatory to rule out mass lesions as a cause for 
myelopathy. The most frequently reported abnoramlites is T2 hyperintensities which 
become more pronounced after contrast (Lukjanowicz &Brzosko,2009)(Provenzale et 
al.,1994)(Boumpas et al.,1990)(Salmaggi et al,1994). In a group of patients the intial MRI can 
be normal especially if it was done early. If the initial MRI is normal repeat study in 2-7 days 
after onset is recommended (Lukjanowicz &Brzosko,2009).  Brain MRI is indicated when 
there is associated neurological symptoms and to help differentiating it from multiple 
sclerosis. 
Cerbrospinal fluid examination is recommended to rule out infectious aetiology 
(EULAR,2010). In 50-70% of cases mild CSF abnormalities are seen including mild 
lymphocytosis and elevated protein with normal glucose. 
An inflammatory CSF with granulocytes pleocytosis, elevated protein and low glucose is 
reported with lupus myelitis especially with longitudinal myelitis. In the presence of this 
finding a carful exclusion of infectious cause is mandatory. 
In the presence of longitudinal myelitis and associated optic neuritis serum should be send 
for anti neuromyelitis antibodies( anti- NMO IgG) to rule out the presence of neuromyelitis 
optica. Anti NMO IgG is a highly sensitive and specific antibody that target aquaporin 4 the 
main water channel in the CNS. 
An aggressive treatment with immunosuppressive is recommended in a setting of ATM.  
The presence of inflammatory CSF should not delay the start of immunosuppressive. In 
that case a combined treatment of antimicrobial with immunosuppressive is 
recommended waiting for the culture results. Antimicrobial should be discontinued once 
infection is ruled out.  
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Treatment with intravenous steroid should be initiated followed by cyclophosphamide with 
oral steroid. 
The treatment should be initiated early in the disease course.  
Plasmapheresis has been used with immunosuppressive medication in severe cases in 
particular in patient with of longitudinal myelitis ((D’Cruz et al.,2004). Although an earlier 
reports by Kovacs showed patients who had combined treatment of steroid, 
immunosuppressive and plasmapheresis did worse than patient who had only steroid with 
or without imunnosupressive ( Kovacs et al.,2000). This is may be because patients who had 
aggressive treatments with three modalities had higher disease activity at the onset of 
myelitis. 
In the presence of Apl anticoagulant therapy is recommended with the immunosuppressive 
therapy. Patients with apl and Transverse myelitis who had combination therapy of 
immunosuppressive and anticoagulant have good functional outcome (D’Cruz et al.,2004 ). 
The functional outcome is good for patient who had early treatment. The presence of 
longitudinal transverse myelitis is associated with poor functional prognosis 
(Gertner,2007)(Kimura et al.,2002). 
7.7 Movement’s disorders 
The most frequently reported movement disorder with SLE patient is chorea. It has been 
linked to antiphospholipid antibodies. Other causes of chorea such as hereditary, metabolic, 
endocrine causes should be excluded. Brain imaging is indicated to rule out structural 
causes in the presence of focal neurological signs.  
Patient need to be treated symptomatically with dopamine antagonist and in severe cases 
the use of glucocoticoid and immunosuppressive therapy is recommended. In the presence 
of antiphospholipid antibodies patient need to be on antiplatelets or anticoagulants 
depending on the presence of other APS related symptoms. 
Parkinsonism is also reported in association with SLE in multiple cases. Usually it is 
associated with severe multisystem CNS involvements. The good response of the reported 
cases to immunosuppressive therapy suggests that it is a manifestation of the disease not a 
coincidence of Parkinson disease and SLE. 
7.8 Peripheral nervous system Involvements 
Peripheral neuropathy is the most frequent reported peripheral nervous system ( PNS ) 
involvement with SLE. The most frequent type is sensory neuropathy followed by 
sensorimotor neuropathy then pure motor neuropathy (Goransson et al.,2006).A subset of 
SLE patients may present with sensory symptoms and still have normal NCS. This is 
because the NCS evaluate the large myelinated fibers and the presence of normal study does 
not rule out small fiber neuropathy. In studies when symptomatic patients with negative 
NCS had skin biopsy an evidence of small fiber nruropathy was found ( Goransson et 
al.,2006)(Omdal et al.,2002). This indicates that small fiber neuropathy is the cause of the 
symptomatic patients with normal NCS. Managements of peripheral neuropathy include 
symptomatic treatments for neuropathic pain as well glucocorticoid with or without 
immunosuppressive therapy depending on the severity of the disease.  In the presence of 
severe cases, or failure of conventional treatments other modalities such as plasmaphersis, 
intravenous immunoglobulin and rituximab can be used. 
Other PNS involvements by SLE are much less. Patient may present with mononeuritis 
multiplex, acute demylenating polyradiculopathy, chronic demylinating polyradiculopathy 
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and myasthenia gravis also reported. The managements of those patients will be the same as 
non SLE patients. 
8. Prognosis 
In spite of recent advances in diagnosis and management, NPSLE remain one of the major 
causes of disease related morbidity.  Swedish study of SLE patients did not find difference 
in mortality in SLE patients with or without NP. However patients with NPSLE have more 
functional impairments when compared to non NPSLE patients (Jonsen, 2002). Prompt 
diagnosis and management may played a role in reducing mortality but significant 
morbidity and functional incapacity still a major problem in SLE patients with 
neuropsychiatric symptoms. 
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